TY - JOUR
T1 - NUC-1031 in biliary tract cancer: from bench to bedside and back?
AU - Boyd, Lenka N C
AU - Peters, Godefridus J
AU - Kazemier, Geert
AU - Giovannetti, Elisa
N1 - Funding Information: The authors would like to thank the Bennink Foundation (The Netherlands) and Associazione Italiana per la Ricerca sul Cancro (AIRC, Italy) Publisher Copyright: © 2020, Springer-Verlag GmbH Germany, part of Springer Nature. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - In preclinical models of biliary tract cancer, NUC-1031 showed less potency than gemcitabine, no correlation with potential biomarkers and only moderate additive interaction in combination with cisplatin. These findings should prompt further careful pharmacological and translational studies to better define the purported therapeutic advantage of NUC-1031 over gemcitabine. That would be a more cautious approach than the phase III clinical trial which is planning to enrol 828 patients with biliary tract tumours to compare gemcitabine/cisplatin "conventional" treatment with or without NUC-1031.
AB - In preclinical models of biliary tract cancer, NUC-1031 showed less potency than gemcitabine, no correlation with potential biomarkers and only moderate additive interaction in combination with cisplatin. These findings should prompt further careful pharmacological and translational studies to better define the purported therapeutic advantage of NUC-1031 over gemcitabine. That would be a more cautious approach than the phase III clinical trial which is planning to enrol 828 patients with biliary tract tumours to compare gemcitabine/cisplatin "conventional" treatment with or without NUC-1031.
UR - http://www.scopus.com/inward/record.url?scp=85085570365&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s00280-020-04080-6
DO - https://doi.org/10.1007/s00280-020-04080-6
M3 - Editorial
C2 - 32476108
SN - 0344-5704
VL - 85
SP - 1011
EP - 1014
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 6
ER -